Stock Titan Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–8
- Matches
- 8
- Sources here
- 6
- Companies here
- 1
Active search
8 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Medicus To Continue Phase 2 For SkinJect In Carcinoma With FDA Recommendations; Stock Falls 12%
(RTTNews) - Medicus Pharma Inc. (MDCX), a biotech/life sciences company, on Tuesday announced the receipt of a 'Study May Proceed' notification from the U.S. Food and Drug Administration (FDA), allowing for the initiation of the Phase 2b SKNJCT-005 trial evaluating SkinJect in Gorlin syndrome. …
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the U.S. Food and Drug Administration (“FDA”) …